Your browser doesn't support javascript.
loading
Genomic grade adds prognostic value in invasive lobular carcinoma.
Metzger-Filho, O; Michiels, S; Bertucci, F; Catteau, A; Salgado, R; Galant, C; Fumagalli, D; Singhal, S K; Desmedt, C; Ignatiadis, M; Haussy, S; Finetti, P; Birnbaum, D; Saini, K S; Berlière, M; Veys, I; de Azambuja, E; Bozovic, I; Peyro-Saint-Paul, H; Larsimont, D; Piccart, M; Sotiriou, C.
Afiliación
  • Metzger-Filho O; Breast Cancer Translation Research Laboratory J. C. Heuson, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  • Michiels S; Breast Cancer Translation Research Laboratory J. C. Heuson, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  • Bertucci F; Department of Molecular Oncology, Institut Paoli-Calmettes, Marseille.
  • Catteau A; Ipsogen SA, Marseille, France.
  • Salgado R; Breast Cancer Translation Research Laboratory J. C. Heuson, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  • Galant C; Department of Pathology, Cliniques Universitaires Saint Luc, Brussels, Belgium.
  • Fumagalli D; Breast Cancer Translation Research Laboratory J. C. Heuson, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  • Singhal SK; Breast Cancer Translation Research Laboratory J. C. Heuson, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  • Desmedt C; Breast Cancer Translation Research Laboratory J. C. Heuson, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  • Ignatiadis M; Breast Cancer Translation Research Laboratory J. C. Heuson, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  • Haussy S; Breast Cancer Translation Research Laboratory J. C. Heuson, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  • Finetti P; Department of Molecular Oncology, Institut Paoli-Calmettes, Marseille.
  • Birnbaum D; Department of Molecular Oncology, Institut Paoli-Calmettes, Marseille.
  • Saini KS; Breast Cancer Translation Research Laboratory J. C. Heuson, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  • Berlière M; Department of Pathology, Cliniques Universitaires Saint Luc, Brussels, Belgium.
  • Veys I; Breast Cancer Translation Research Laboratory J. C. Heuson, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  • de Azambuja E; Breast Cancer Translation Research Laboratory J. C. Heuson, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  • Bozovic I; Breast Cancer Translation Research Laboratory J. C. Heuson, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  • Peyro-Saint-Paul H; Ipsogen SA, Marseille, France.
  • Larsimont D; Breast Cancer Translation Research Laboratory J. C. Heuson, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  • Piccart M; Breast Cancer Translation Research Laboratory J. C. Heuson, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  • Sotiriou C; Breast Cancer Translation Research Laboratory J. C. Heuson, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. Electronic address: christos.sotiriou@bordet.be.
Ann Oncol ; 24(2): 377-384, 2013 Feb.
Article en En | MEDLINE | ID: mdl-23028037
ABSTRACT

BACKGROUND:

The prognostic value of histologic grade (HG) in invasive lobular carcinoma (ILC) remains uncertain, and most ILC tumors are graded as HG2. Genomic grade (GG) is a 97-gene signature that improves the prognostic value of HG. This study evaluates whether GG may overcome the limitations of HG in ILC.

METHODS:

Gene expression data were generated from frozen tumor samples, and GG calculated according to the expression of 97 genes. The prognostic value of GG was assessed in a stratified Cox regression model for invasive disease-free survival (IDFS) and overall survival (OS).

RESULTS:

A total of 166 patients were classified by GG. HG classified 33 (20%) tumors as HG1, 120 (73%) as HG2 and 12 (7%) as HG3. GG classified 106 (64%) tumors as GG low (GG1), 29 (17%) as GG high (GG3) and 31 (19%) as equivocal (cases not classified as GG1 or GG3). The median follow-up time was 6.5 years. In multivariate analyses, GG was associated with IDFS [HR(GG3 vs GG1) 5.6 (2.1-15.3); P < 0.001] and OS [HR(GG3 vs GG1) 7.2, 95% CI (1.6-32.2); P = 0.01].

CONCLUSIONS:

GG outperformed HG in ILC and added prognostic value to classic clinicopathologic variables, including nodal status.
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Carcinoma Lobular Tipo de estudio: Prognostic_studies Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2013 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Carcinoma Lobular Tipo de estudio: Prognostic_studies Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2013 Tipo del documento: Article